Zev Binder, M.D., Ph.D.
Research Assistant Professor of Neurosurgery
Scientific Director, Adult Brain Tumor Tissue Bank
Department: Neurosurgery
Graduate Group Affiliations
Contact information
3600 Hamilton Walk
Stemmler Hall
Philadelphia, PA 19104
Stemmler Hall
Philadelphia, PA 19104
Office: 215-573-0837
Publications
Links
Search PubMed for articles
University of Pennsylvania's Center for Cellular Immunotherapies
O'Rourke Laboratory Website
Search PubMed for articles
University of Pennsylvania's Center for Cellular Immunotherapies
O'Rourke Laboratory Website
Education:
BS (Biochemistry)
University of California, Davis, 2004.
M.D.
Pennsylvania State University College of Medicine, 2008.
Ph.D. (Chemical and Biomolecular Engineering)
Johns Hopkins University, 2014.
Permanent linkBS (Biochemistry)
University of California, Davis, 2004.
M.D.
Pennsylvania State University College of Medicine, 2008.
Ph.D. (Chemical and Biomolecular Engineering)
Johns Hopkins University, 2014.
Description of Research Expertise
Dr. Binder is a Research Assistant Professor, working with Dr. O'Rourke since 2015. He received a B.S. degree in Biochemistry from the University of California at Davis, an M.D. from Pennsylvania State University, and a Ph.D. in Chemical and Biomolecular Engineering from Johns Hopkins University. Dr. Binder's research focuses on translational GBM research with an emphasis on immuno-oncology. He also works on GBM model development, characterization, and incorporation into the ongoing research.Selected Publications
Fathi Kazerooni A, Akbari H, Hu X, Bommineni V, Grigoriadis D, Toorens E, Sako C, Mamourian E, Ballinger D, Sussman R, Singh A, Verginadis II, Dahmane N, Koumenis C, Binder ZA, Bagley SJ, Mohan S, Hatzigeorgiou A, O'Rourke DM, Ganguly T, De S, Bakas S, Nasrallah MP, Davatzikos C. : The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic drivers. Communications Medicine 5(1), March 2025.Sabrina L. Begley, Donald M. O’Rourke, and Zev A. Binder: CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials. Molecular Therapy March 2025.
Sun Y, Wang X, Zhang DY, Zhang Z, Bhattarai JP, Wang Y, Park KH, Dong W, Hung YF, Yang Q, Zhang F, Rajamani K, Mu S, Kennedy BC, Hong Y, Galanaugh J, Sambangi A, Kim SH, Wheeler G, Gonçalves T, Wang Q, Geschwind DH, Kawaguchi R, Viaene AN, Helbig I, Kessler SK, Hoke A, Wang H, Xu F, Binder ZA, Isaac Chen H, Pai EL, Stone S, Nasrallah MP, Christian KM, Fuccillo M, Toni N, Wu Z, Cheng HJ, O'Rourke DM, Ma M, Ming GL, Song H. : Brain-wide neuronal circuit connectome of human glioblastoma. Nature Jan 2025.
Till JE, Seewald NJ, Yazdani Z, Wang Z, Ballinger D, Samberg H, Dandu S, Macia C, Yin M, Abdalla A, Prior T, Shah S, Patel T, McCoy E, Mansour M, Wills CA, Bochenek V, Serrano J, Snuderl M, Phillips RE, O'Rourke DM, Amankulor NM, Nabavizadeh A, Desai AS, Gollomp K, Binder ZA, Zhou W, Bagley SJ, Carpenter EL: Corticosteroid-Dependent Association between Prognostic Peripheral Blood Cell-Free DNA Levels and Neutrophil-Mediated NETosis in Patients with Glioblastoma. Clinical Cancer Research Jan 2025.
Meghan Logun, Xin Wang, Yusha Sun, Stephen J Bagley, Nannan Li, Arati Desai, Daniel Y Zhang, MacLean P Nasrallah, Emily Ling-Lin Pai, Bike Su Oner, Gabriela Plesa, Donald Siegel, Zev A Binder*, Guo-Li Ming*, Hongjun Song*, Donald M O'Rourke*: Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell S1934-5909(24): 00409-0, Dec 2024 Notes: * co-senior author.
Daniel H Park, Pratik S Bhojnagarwala, Kevin Liaw, Devivasha Bordoloi, Nicholas J Tursi, Shushu Zhao, Zev A Binder, Donald O’Rourke, and David B Weiner: Novel tri-specific T-cell engager targeting IL-13Rα2 and EGFRvIII provides long-term survival in heterogeneous GBM challenge and promotes antitumor cytotoxicity with patient immune cells. Journal for ImmunoTherapy of Cancer 12(12): e009604, Dec 2024.
Akbari H, Bakas S, Sako C, Fathi Kazerooni A, Villanueva-Meyer J, Garcia JA, Mamourian E, Liu F, Cao Q, Shinohara RT, Baid U, Getka A, Pati S, Singh A, Calabrese E, Chang S, Rudie J, Sotiras A, LaMontagne P, Marcus DS, Milchenko M, Nazeri A, Balana C, Capellades J, Puig J, Badve C, Barnholtz-Sloan JS, Sloan AE, Vadmal V, Waite K, Ak M, Colen RR, Park YW, Ahn SS, Chang JH, Choi YS, Lee SK, Alexander GS, Ali AS, Dicker AP, Flanders AE, Liem S, Lombardo J, Shi W, Shukla G, Griffith B, Poisson LM, Rogers LR, Kotrotsou A, Booth TC, Jain R, Lee M, Mahajan A, Chakravarti A, Palmer JD, DiCostanzo D, Fathallah-Shaykh H, Cepeda S, Santonocito OS, Di Stefano AL, Wiestler B, Melhem ER, Woodworth GF, Tiwari P, Valdes P, Matsumoto Y, Otani Y, Imoto R, Aboian M, Koizumi S, Kurozumi K, Kawakatsu T, Alexander K, Satgunaseelan L, Rulseh AM, Bagley SJ, Bilello M, Binder ZA, Brem S, Desai AS, Lustig RA, Maloney E, Prior T, Amankulor N, Nasrallah MLP, O'Rourke DM, Mohan S, Davatzikos C; ReSPOND consortium: Machine Learning-based Prognostic Subgrouping of Glioblastoma: A Multi-center Study. Neuro-Oncology Dec 2024 Notes: [Online Ahead of Print]; doi: 10.1093/neuonc/noae260.
Nannan Li, Jesse L. Rodriguez, Yibo Yin, Meghan T Logun, Logan Zhang, Shengkun Yu, Kelly A. Hicks, Vicky Zhang, Laura Zhang, Chuncheng Xie, Jiabin Wang, Joseph A Fraietta, Zev A. Binder*, Zhiguo Lin*, and Donald M. O’Rourke*: Armored Bicistronic CAR T Cells with Dominant-negative TGF-β Receptor II to Overcome Resistance in Glioblastoma. Mol Ther 32(10): 3522-3538, Oct 2024 Notes: * co-senior author.
Elinor Willis, Jillian Verrelle, Esha Banerjee, Charles-Antoine Assenmacher, James C. Tarrant, Nicholas Skuli, Moriah L. Jacobson, Donald M. O’Rouke, Zev A. Binder*, and Enrico Radaelli1*: Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Veterinary Pathology 61(4): 664-674, Jul 2024 Notes: * co-senior author.
Jingxian Liu, Song Cao, Kathleen J. Imbach, Marina A. Gritsenko, Tung-Shing M. Lih, Jennifer E. Kyle*, Tomer M. Yaron*, Zev A. Binder*, Yize Li*, Ilya Strunilin*, Yi-Ting Wang*, Chia-Feng Tsai*, Weiping Ma*, Lijun Chen*, Natalie M. Clark, Andrew Shinkle, Nataly Naser Al Deen, Wagma Caravan, Andrew Houston, Faria A. Simin, Matthew A. Wyczalkowski, Liang-Bo Wang, Erik Storrs, Siqi Chen, Ritvik Illindala, Yuping D. Li, Reyka G. Jayasinghe, Dmitry Rykunov, Sandra L. Cottingham, Rosalie K. Chu, Karl K. Weitz, Ronald J. Moore, Tyler Sagendorf, Vladislav A. Petyuk, Michael Nestor, Lisa M. Bramer, Kelly G. Stratton, Athena A. Schepmoes, Sneha P. Couvillion, Josie Eder, Young-Mo Kim, Yuqian Gao, Thomas L. Fillmore, Rui Zhao, Matthew E. Monroe, Austin N. Southard-Smith, Yang E. Li, Rita Jui-Hsien Lu, Jared L. Johnson, Maciej Wiznerowicz, Galen Hostetter, Chelsea J. Newton, Karen A. Ketchum, Ratna R. Thangudu, Jill S. Barnholtz-Sloan, Pei Wang, David Fenyö, Eunkyung An, Mathangi Thiagarajan, Ana I. Robles, D. R. Mani, Richard D. Smith, Eduard Porta-Pardo, Lewis C. Cantley, Antonio Iavarone, Feng Chen, Mehdi Mesri, MacLean P. Nasrallah, Hui Zhang, Adam C. Resnick, Milan G. Chheda, Karin D. Rodland, Tao Liu, Li Ding, Philadelphia Coalition for a Cure, Clinical Proteomic Tumor Analysis Consortium: Multi-scale signaling and tumor evolution in high-grade gliomas. Cancer Cell 42(7): 1217-1238.e19, Jul 2024 Notes: * equal contribution.